Navigation Links
PharmAthene to Present at the BIO CEO & Investor Conference 2008
Date:2/6/2008

ANNAPOLIS, Md., Feb. 6 /PRNewswire-FirstCall/ -- PharmAthene, Inc., (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that David P. Wright, President and Chief Executive Officer of PharmAthene, will present at the BIO CEO & Investor Conference 2008, in New York, NY on Wednesday, February 13, 2008 at 2:00 p.m. The presentation is scheduled to take place in the Basildon Room at the Waldorf Astoria Hotel.

PharmAthene's presentation will be available via webcast on the company's website at http://www.pharmathene.com. A link to access the webcast will be accessible from both the homepage and the investor relations pages of the PharmAthene corporate website. For assistance, contact Stacey Jurchison at 410-269-2610.

About PharmAthene, Inc.

PharmAthene (Amex: PIP) was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead programs include Valortim(TM) for the prevention and treatment of anthrax infection and Protexia(R) for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. For more information on PharmAthene, please visit http://www.pharmathene.com.


'/>"/>
SOURCE PharmAthene Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
6. Avicena Group to Present at Noble Financial Conference
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CEL-SCI to Present at the Noble Financial Conference
11. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... SAN DIEGO , May 20, 2013  Dr. ... the field of nucleic acid research, recently launched a ... Zone In with Zon ( zon.trilinkbiotech.com ), focuses on ... posts include interviews with industry thought leaders, discussions of ... publications and more. Dr. Zon (PhD ...
(Date:5/20/2013)... York, NY (PRWEB) May 20, 2013 With ... Cleaning Products said that although bed bugs need to be ... process will not compromise a person's health. And so to ... guide how to get rid of bed bugs ... its non-pesticide bed bug spray it called Bed Bug Bully. ...
(Date:5/20/2013)... May 20, 2013 Cempra, Inc. (Nasdaq: ... differentiated antibiotics to meet critical medical needs in ... it presented data at the American Thoracic Society ... demonstrating the antibacterial and enhanced immunomodulatory ... Phase 2 clinical trial in outpatients with community ...
(Date:5/20/2013)... Rhythm announced today the results of a ... novel ghrelin agonist for the treatment of diabetic gastroparesis ... RM-131 significantly accelerates early gastric emptying and reduces upper ... diabetic gastroparesis. The findings were presented at the Digestive ... and recently published in Clinical Gastroenterology and ...
Breaking Biology Technology:Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3
... ... cGMP manufacturer, announced that the company is in the initial phases of a multi-year ... Ingredient (API) manufacturing facility located in Riverview, Michigan. Expansions will include a new reactor ... ...
... , CRANBURY, N.J., Sept. 30 Amicus Therapeutics (Nasdaq: ... 1 study of AT2220 (1-deoxynojirimycin HCl), its investigational drug in ... objective of this study is to evaluate the pharmacokinetics of ... U.S. Food and Drug Administration (FDA) has agreed to Amicus, ...
... Despite a number of key issues such as ... and feed uses, global use of biofuels is excepted to ... new global analysis released today by Hart,s Global Biofuels Center. ... of total biofuels use of more than 35%. Brazil will ...
Cached Biology Technology:Ash Stevens Plans $6 Million Facility Expansion to Bolster CMC Capabilities 2Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 2Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 3Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 4Global Biofuels Growth to Double by 2015 2Global Biofuels Growth to Double by 2015 3Global Biofuels Growth to Double by 2015 4
(Date:5/17/2013)... Scientists investigating the interaction of a group of proteins ... damage have identified a new target that could increase ... the University,s School of Biochemistry and published in the ... Reviews, could eventually lead to new therapies for stroke ... earlier work by the team which identified a protein, ...
(Date:5/17/2013)... MD The Federation of American Societies for Experimental ... National Institutes of Health (NIH) funding trends highlighting the ... support critical research. The FASEB analysis follows a May ... Collins, MD, PhD, who testified that the $1.6 billion ... sequestration is "having a substantial impact on the scientific ...
(Date:5/16/2013)... MD FASEB MARC (Maximizing Access to Research ... for The Society for Developmental Biology (SDB) 72nd ... 2013. These awards are meant to promote the ... groups into the mainstream of the basic science ... scientists at the SDB 2013 Annual Meeting. , ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2
... pleased to announce an exclusive commercial license agreement ... plants and with important implications for crop improvement. ... is licensing the technology to Dow AgroSciences. Dow ... Chemical Company (NYSE: DOW), entered into an exclusive ...
... evolve for months after a traumatic brain injury (TBI), ... trauma, new research led by the University of Melbourne, ... Victorian Neurotrauma Initiative is published in the latest issue ... Around 400,000 Australians have a disability related to ...
... help from their female friends are far more successful as ... new study. , Previous research into reproductive success in animal ... benefits of inherited genetic characteristics, while others show the benefits ... uncle or other unrelated helpers. , The new ...
Cached Biology News:Dow Agrosciences licenses exclusive novel crop enhancement technology 2Study provides treatment hope for long term effects of brain trauma 2Successful mothers get help from their friends: Dolphin study 2
...
... fully licensed, high throughput, water bath thermal cycler ... 24 microplates. This equates to 9,216 reactions per ... robotic arm rapidly transfers a basket of plates ... times that are considerably faster than those of ...
anti-Yan 8B12H9...
Proliferin (N-14)...
Biology Products: